Amber Stutz, MD
Neurology · Greenville, SCNPI 1952748758
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $25,763 with a category attached, or 97.0%. Medtronic accounts for 97.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $25,079 and has fallen 99.2% since, to $199 in 2025.
Across 30 payments — averaging $858.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$25K
- Amneal Pharmaceuticals LLC$206
- Neurocrine Biosciences, Inc.$162
- Boston Scientific$117
- Acadia Pharmaceuticals Inc$51
- MDD US Operations, LLC$37
- plus $165 from 8 others
What the payments were for
- Speaking & faculty fees$120%
- Grants$25,00097%
- Food & beverage$7513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 3 | $25,024 |
| Amneal Pharmaceuticals LLC | 5 | $206 |
| Neurocrine Biosciences, Inc. | 3 | $162 |
| Boston Scientific | 4 | $117 |
| Acadia Pharmaceuticals Inc | 3 | $51 |
| MDD US Operations, LLC | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $29 |
| Acorda Therapeutics, Inc | 2 | $29 |
| Biogen | 1 | $18 |
| Saol Therapeutics Inc. | 1 | $17 |
| AbbVie | 1 | $17 |
| AstraZeneca | 1 | $13 |
| Abbott | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,763 in reported general payments places this provider in the 85th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 59 | $118,201 |
| IngrezzaValbenazine Tosylate | 14 | $106,917 |
| NuplazidPimavanserin Tartrate | 11 | $53,963 |
| Droxidopa | 36 | $42,426 |
| NeuproRotigotine | 13 | $30,147 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 561 | $24,181 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 109 | $8,714 |
| Rivastigmine | 40 | $8,384 |
| Midodrine Hcl | 86 | $5,394 |
| Carbidopa | 23 | $4,810 |
| Propranolol Hcl ErPropranolol Hcl | 78 | $4,087 |
| Rasagiline Mesylate | 14 | $3,675 |
| Ropinirole ErRopinirole Hcl | 17 | $2,942 |
| Primidone | 67 | $2,724 |
| AmantadineAmantadine Hcl | 52 | $2,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $206 | $118,20159 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $162 | $106,91714 claims |
| Acadia Pharmaceuticals IncNuplazid | $51 | $53,96311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 270 neurology providers in South Carolina.
Other neurology in Greenville
- Mary HughesGreenville$404K
- Fredy RevillaGreenville$208K
- Kathleen WoschkolupGreenville$97K
- Sandip JainGreenville$43K
- John AbsherGreenville$30K
- John PorterGreenville$17K
- Brian ThompsonGreenville$11K
- John BakerSumter$779K
- Robert CarlileSummerville$428K
- Jose CardenasAiken$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.